{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T12:31:00Z","timestamp":1792672260831,"version":"4.5.0"},"reference-count":91,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2020,10,13]],"date-time":"2020-10-13T00:00:00Z","timestamp":1602547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,10,13]],"date-time":"2020-10-13T00:00:00Z","timestamp":1602547200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100000737","name":"University of Exeter","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100000737","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Neurol Neurosci Rep"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Purpose of Review<\/jats:title><jats:p>To review the incidence, treatment and genetics of psychosis in people with mild cognitive impairment (MCI) and Alzheimer\u2019s disease (AD).<\/jats:p><\/jats:sec><jats:sec><jats:title>Recent Findings<\/jats:title><jats:p>Psychosis in Alzheimer\u2019s disease (AD) has an incidence of ~\u200910% per year. There is limited evidence regarding psychological interventions. Pharmacological management has focused on atypical antipsychotics, balancing modest benefits with evidence of long-term harms. The 5HT2A inverse agonist pimavanserin appears to confer benefit in PD psychosis with initial evidence of benefit in AD. Cholinesterase inhibitors give modest benefits in DLB psychosis. The utility of muscarinic agonists, lithium, glutamatergic and noradrenergic modulators needs further study.<\/jats:p><\/jats:sec><jats:sec><jats:title>Summary<\/jats:title><jats:p>Recent work has confirmed the importance of psychosis in MCI as well as AD. The lack of evidence regarding psychological therapies is an urgent knowledge gap, but there is encouraging evidence for emerging pharmacological treatments. Genetics will provide an opportunity for precision medicine and new treatment targets.<\/jats:p><\/jats:sec>","DOI":"10.1007\/s11910-020-01074-y","type":"journal-article","created":{"date-parts":[[2020,10,13]],"date-time":"2020-10-13T09:03:07Z","timestamp":1602579787000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":57,"title":["Psychosis in Alzheimer\u2019s Disease"],"prefix":"10.1007","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0022-5632","authenticated-orcid":false,"given":"Clive","family":"Ballard","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen C.","family":"Kales","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Constantine","family":"Lyketsos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dag","family":"Aarsland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Byron","family":"Creese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger","family":"Mills","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hilde","family":"Williams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert A.","family":"Sweet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,10,13]]},"reference":[{"key":"1074_CR1","doi-asserted-by":"crossref","first-page":"2673","DOI":"10.1016\/S0140-6736(17)31363-6","volume":"390","author":"G Livingston","year":"2017","unstructured":"Livingston G, Sommerlad A, Orgeta V, Costafreda SG, Huntley J, Ames D, et al. Dementia prevention, intervention, and care. Lancet. 2017;390:2673\u2013734.","journal-title":"Lancet"},{"key":"1074_CR2","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1159\/000017228","volume":"11","author":"M Haupt","year":"2000","unstructured":"Haupt M, Kurz A, Janner M. A 2-year follow-up of behavioural and psychological symptoms in Alzheimer's disease. Dement Geriatr Cogn Disord. 2000;11:147\u201352.","journal-title":"Dement Geriatr Cogn Disord"},{"issue":"Suppl 4","key":"1074_CR3","first-page":"S44","volume":"155","author":"C Ballard","year":"1999","unstructured":"Ballard C, Gray A, Ayre G. Psychotic symptoms, aggression and restlessness in dementia. Rev Neurol (Paris). 1999;155(Suppl 4):S44\u201352.","journal-title":"Rev Neurol (Paris)"},{"key":"1074_CR4","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1097\/00019442-200002000-00004","volume":"8","author":"DV Jeste","year":"2000","unstructured":"Jeste DV, Finkel SI. Psychosis of Alzheimer\u2019s disease and related dementias: diagnostic criteria for a distinct syndrome. Am J Geriatr Psychiatry. 2000;8:29\u201334.","journal-title":"Am J Geriatr Psychiatry"},{"key":"1074_CR5","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1097\/00019442-200301000-00011","volume":"11","author":"I Leroi","year":"2003","unstructured":"Leroi I, Voulgari A, Breitner JC, et al. The epidemiology of psychosis in dementia. Am J Geriatr Psychiatry. 2003;11:83\u201391.","journal-title":"Am J Geriatr Psychiatry"},{"key":"1074_CR6","doi-asserted-by":"crossref","first-page":"319","DOI":"10.3233\/JAD-130596","volume":"38","author":"S Van der Mussele","year":"2014","unstructured":"Van der Mussele S, Marien P, Saerens J, et al. Behavioral syndromes in mild cognitive impairment and Alzheimer's disease. J Alzheimers Dis. 2014;38:319\u201329.","journal-title":"J Alzheimers Dis"},{"key":"1074_CR7","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1159\/000351009","volume":"37","author":"LG Apostolova","year":"2014","unstructured":"Apostolova LG, Di LJ, Duffy EL, et al. Risk factors for behavioral abnormalities in mild cognitive impairment and mild Alzheimer\u2019s disease. Dement Geriatr Cogn Disord. 2014;37:315\u201326.","journal-title":"Dement Geriatr Cogn Disord"},{"key":"1074_CR8","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1017\/S1041610217000874","volume":"30","author":"CE Fischer","year":"2018","unstructured":"Fischer CE, Ag\u00fcera-Ortiz L. Psychosis and dementia: risk factor, prodrome, or cause? Int Psychogeriatr. 2018;30:209\u201319.","journal-title":"Int Psychogeriatr"},{"key":"1074_CR9","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1001\/jama.288.12.1475","volume":"288","author":"CG Lyketsos","year":"2002","unstructured":"Lyketsos CG, Lopez O, Jones B, Fitzpatrick AL, Breitner J, DeKosky S. Prevalence of neuropsychiatric symptoms in dementia and mild cognitive impairment. Results from the cardiovascular health study. JAMA. 2002;288:1475\u201383.","journal-title":"JAMA"},{"key":"1074_CR10","doi-asserted-by":"crossref","unstructured":"Creese B, Griffiths A, Brooker H, et al. Profile of mild behavioral impairment and factor structure of the mild behavioral impairment checklist in cognitively normal older adults. PsyArxiv. 2019.","DOI":"10.31234\/osf.io\/jhx5k"},{"key":"1074_CR11","doi-asserted-by":"crossref","unstructured":"\u2022 Creese B, Brooker H, Ismail Z, et al. Mild behavioral impairment as a marker of cognitive decline in cognitively normal older adults. Am J Geriatr Psychiatry. 2019. A large population based study showing neuropsychiatric symptoms are associated with cognitive changes in older adults without clinically significant cognitive impairment.","DOI":"10.1016\/j.jagp.2019.01.215"},{"key":"1074_CR12","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1016\/j.jagp.2013.01.051","volume":"21","author":"J Vilalta-Franch","year":"2013","unstructured":"Vilalta-Franch J, L\u00f3pez-Pousa S, Calv\u00f3-Perxas L, Garre-Olmo J. Psychosis of Alzheimer disease: prevalence, incidence, persistence, risk factors, and mortality. Am J Geriatr Psychiatry. 2013;21:1135\u201343.","journal-title":"Am J Geriatr Psychiatry"},{"key":"1074_CR13","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1017\/S1041610297004201","volume":"9","author":"C Ballard","year":"1997","unstructured":"Ballard C, O'Brien J, Coope B, Fairbairn A, Abid F, Wilcock G. A prospective study of psychotic symptoms in dementia sufferers: psychosis in dementia. Int Psychogeriatr. 1997;9:57\u201364.","journal-title":"Int Psychogeriatr"},{"key":"1074_CR14","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1001\/archneur.62.10.1601","volume":"62","author":"N Scarmeas","year":"2005","unstructured":"Scarmeas N, Brandt J, Albert M, Hadjigeorgiou G, Papadimitriou A, Dubois B, et al. Delusions and hallucinations are associated with worse outcome in Alzheimer disease. Arch Neurol. 2005;62:1601\u20138.","journal-title":"Arch Neurol"},{"key":"1074_CR15","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1097\/JGP.0b013e3181e446c8","volume":"19","author":"JE Emanuel","year":"2011","unstructured":"Emanuel JE, Lopez OL, Houck PR, Becker JT, Weamer EA, DeMichele-Sweet MAA, et al. Trajectory of cognitive decline as a predictor of psychosis in early Alzheimer disease in the cardiovascular health study. Am J Geriatr Psychiatry. 2011;19:160\u20138.","journal-title":"Am J Geriatr Psychiatry"},{"key":"1074_CR16","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1176\/appi.ajp.2014.14040480","volume":"172","author":"ME Peters","year":"2015","unstructured":"Peters ME, Schwartz S, Han D, Rabins PV, Steinberg M, Tschanz JT, et al. Neuropsychiatric symptoms as predictors of progression to severe Alzheimer\u2019s dementia and death: the Cache County dementia progression study. Am J Psychiatr. 2015;172:460\u20135.","journal-title":"Am J Psychiatr"},{"key":"1074_CR17","doi-asserted-by":"crossref","first-page":"2022","DOI":"10.1176\/appi.ajp.162.11.2022","volume":"162","author":"SA Ropacki","year":"2005","unstructured":"Ropacki SA, Jeste DV. Epidemiology of and risk factors for psychosis of Alzheimer\u2019s disease: a review of 55 studies published from 1990 to 2003. Am J Psychiatr. 2005;162:2022\u201330.","journal-title":"Am J Psychiatr"},{"key":"1074_CR18","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1176\/ajp.152.9.1349","volume":"152","author":"PN Tariot","year":"1995","unstructured":"Tariot PN, Mack JL, Patterson MB, Edland SD, Weiner MF, Fillenbaum G, et al. The behavior rating scale for dementia of the consortium to establish a registry for Alzheimer\u2019s disease. Am J Psychiatry. 1995;152:1349\u201357.","journal-title":"Am J Psychiatry"},{"key":"1074_CR19","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1177\/089198878800100104","volume":"1","author":"EH Rubin","year":"1988","unstructured":"Rubin EH, Drevets WC, Burke WJ. The nature of psychotic symptoms in senile dementia of the Alzheimer type. J Geriatr Psychiatry Neurol. 1988;1:16\u201320.","journal-title":"J Geriatr Psychiatry Neurol"},{"key":"1074_CR20","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1002\/gps.448","volume":"16","author":"CG Lyketsos","year":"2001","unstructured":"Lyketsos CG, Sheppard J-ME, Steinberg M, Tschanz JAT, Norton MC, Steffens DC, et al. Neuropsychiatric disturbance in Alzheimer's disease clusters into three groups: the Cache County study. Int J Geriatr Psychiatry. 2001;16:1043\u201353.","journal-title":"Int J Geriatr Psychiatry"},{"key":"1074_CR21","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.jalz.2015.05.017","volume":"12","author":"Z Ismail","year":"2016","unstructured":"Ismail Z, Smith EE, Geda Y, Sultzer D, Brodaty H, Smith G, et al. Neuropsychiatric symptoms as early manifestations of emergent dementia: provisional diagnostic criteria for mild behavioral impairment. Alzheimers Dement. 2016;12:195\u2013202.","journal-title":"Alzheimers Dement"},{"key":"1074_CR22","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1176\/jnp.3.4.371","volume":"3","author":"DW Gilley","year":"1991","unstructured":"Gilley DW, Whalen ME, Wilson RS, Bennett DA. Hallucinations and associated factors in Alzheimer\u2019s disease. J Neuropsychiatr Clin Neurosci. 1991;3:371\u20136.","journal-title":"J Neuropsychiatr Clin Neurosci"},{"key":"1074_CR23","doi-asserted-by":"crossref","first-page":"2300","DOI":"10.1212\/WNL.44.12.2300","volume":"44","author":"Y Stern","year":"1994","unstructured":"Stern Y, Albert M, Brandt J, Jacobs DM, Tang MX, Marder K, et al. Utility of extrapyramidal signs and psychosis as predictors of cognitive and functional decline, nursing home admission, and death in Alzheimer\u2019s disease. Neurology. 1994;44:2300.","journal-title":"Neurology"},{"key":"1074_CR24","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1159\/000342119","volume":"34","author":"LP Wadsworth","year":"2012","unstructured":"Wadsworth LP, Lorius N, Donovan NJ, Locascio JJ, Rentz DM, Johnson KA, et al. Neuropsychiatric symptoms and global functional impairment along the Alzheimer\u2019s continuum. Dement Geriatr Cogn Disord. 2012;34:96\u2013111.","journal-title":"Dement Geriatr Cogn Disord"},{"key":"1074_CR25","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1212\/WNL.54.10.1965","volume":"54","author":"JS Paulsen","year":"2000","unstructured":"Paulsen JS, Salmon DP, Thal LJ, Romero R, Weisstein-Jenkins C, Galasko D, et al. Incidence of and risk factors for hallucinations and delusions in patients with probable AD. Neurology. 2000;54:1965\u201371.","journal-title":"Neurology"},{"key":"1074_CR26","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1017\/S1041610208007734","volume":"21","author":"EA Weamer","year":"2009","unstructured":"Weamer EA, Emanuel JE, Varon D, Miyahara S, Wilkosz PA, Lopez OL, et al. The relationship of excess cognitive impairment in MCI and early Alzheimer\u2019s disease to the subsequent emergence of psychosis. Int Psychogeriatr. 2009;21:78\u201385.","journal-title":"Int Psychogeriatr"},{"key":"1074_CR27","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/j.biopsych.2013.08.020","volume":"75","author":"PS Murray","year":"2014","unstructured":"Murray PS, Kumar S, DeMichele-Sweet MAA, et al. Psychosis in Alzheimer\u2019s disease. Biol Psychiatry. 2014;75:542\u201352.","journal-title":"Biol Psychiatry"},{"key":"1074_CR28","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.jagp.2013.03.014","volume":"23","author":"LB Zahodne","year":"2015","unstructured":"Zahodne LB, Ornstein K, Cosentino S, Devanand DP, Stern Y. Longitudinal relationships between Alzheimer disease progression and psychosis, depressed mood, and agitation\/aggression. Am J Geriatr Psychiatry. 2015;23:130\u201340.","journal-title":"Am J Geriatr Psychiatry"},{"key":"1074_CR29","doi-asserted-by":"crossref","first-page":"361","DOI":"10.3233\/JAD-150228","volume":"48","author":"MA Beydoun","year":"2015","unstructured":"Beydoun MA, Beydoun HA, Gamaldo AA, Rostant OS, Dore GA, Zonderman AB, et al. Nationwide inpatient prevalence, predictors, and outcomes of Alzheimer\u2019s disease among older adults in the United States, 2002-2012. J Alzheimers Dis. 2015;48:361\u201375.","journal-title":"J Alzheimers Dis"},{"key":"1074_CR30","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1212\/WNL.58.6.907","volume":"58","author":"RA Sweet","year":"2002","unstructured":"Sweet RA, Nimgaonkar VL, Devlin B, Lopez OL, DeKosky ST. Increased familial risk of the psychotic phenotype of Alzheimer disease. Neurology. 2002;58:907\u201311.","journal-title":"Neurology"},{"key":"1074_CR31","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1001\/archpsyc.60.12.1187","volume":"60","author":"PF Sullivan","year":"2003","unstructured":"Sullivan PF, Kendler KS, Neale MC. Schizophrenia as a complex trait: evidence from a meta-analysis of twin studies. Arch Gen Psychiatry. 2003;60:1187\u201392.","journal-title":"Arch Gen Psychiatry"},{"key":"1074_CR32","first-page":"168","volume":"63","author":"M Gatz","year":"2006","unstructured":"Gatz M, Reynolds CA, Fratiglioni L, et al. Role of genes and environments for explaining Alzheimer disease. JAMA Psychiatry. 2006;63:168\u201374.","journal-title":"JAMA Psychiatry"},{"key":"1074_CR33","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1002\/ana.10999","volume":"55","author":"NL Pedersen","year":"2004","unstructured":"Pedersen NL, Gatz M, Berg S, Johansson B. How heritable is Alzheimer\u2019s disease late in life? Findings from Swedish twins. Ann Neurol. 2004;55:180\u20135.","journal-title":"Ann Neurol"},{"key":"1074_CR34","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1093\/brain\/awq001","volume":"133","author":"RA Sweet","year":"2010","unstructured":"Sweet RA, Bennett DA, Graff-Radford NR, Mayeux R, the National Institute on Aging Late-Onset Alzheimer's Disease Family Study Group. Assessment and familial aggregation of psychosis in Alzheimer\u2019s disease from the National Institute on Aging Late Onset Alzheimer's Disease Family Study. Brain. 2010;133:1155\u201362.","journal-title":"Brain"},{"key":"1074_CR35","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1097\/00019442-200507000-00011","volume":"13","author":"SA Bacanu","year":"2005","unstructured":"Bacanu SA, Devlin B, Chowdari KV, DeKosky ST, Nimgaonkar VL, Sweet RA. Heritability of psychosis in Alzheimer disease. Am J Geriatr Psychiatry. 2005;13:624\u20137.","journal-title":"Am J Geriatr Psychiatry"},{"key":"1074_CR36","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1002\/ajmg.b.30515","volume":"144b","author":"P Hollingworth","year":"2007","unstructured":"Hollingworth P, Hamshere ML, Holmans PA, et al. Increased familial risk and genomewide significant linkage for Alzheimer\u2019s disease with psychosis. Am J Med Genet B Neuropsychiatr Genet. 2007;144b:841\u20138.","journal-title":"Am J Med Genet B Neuropsychiatr Genet"},{"key":"1074_CR37","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1038\/mp.2011.125","volume":"17","author":"P Hollingworth","year":"2012","unstructured":"Hollingworth P, Sweet R, Sims R, et al. Genome-wide association study of Alzheimer\u2019s disease with psychotic symptoms. Mol Psychiatry. 2012;17:1316\u201327.","journal-title":"Mol Psychiatry"},{"key":"1074_CR38","doi-asserted-by":"crossref","unstructured":"DeMichele-Sweet MAA, Weamer EA, Klei L, et al. Genetic risk for schizophrenia and psychosis in Alzheimer disease. Mol Psychiatry. 2017.","DOI":"10.1038\/mp.2017.81"},{"key":"1074_CR39","doi-asserted-by":"crossref","first-page":"409","DOI":"10.3233\/JAD-1999-1605","volume":"1","author":"KL Jordan-Sciutto","year":"1999","unstructured":"Jordan-Sciutto KL, Morgan K, Bowser R. Increased cyclin G1 immunoreactivity during Alzheimer\u2019s disease. J Alzheimers Dis. 1999;1:409\u201317.","journal-title":"J Alzheimers Dis"},{"key":"1074_CR40","doi-asserted-by":"crossref","first-page":"4816","DOI":"10.1002\/j.1460-2075.1994.tb06807.x","volume":"13","author":"K Okamoto","year":"1994","unstructured":"Okamoto K, Beach D. Cyclin G is a transcriptional target of the p53 tumor suppressor protein. EMBO J. 1994;13:4816\u201322.","journal-title":"EMBO J"},{"key":"1074_CR41","doi-asserted-by":"crossref","unstructured":"Creese B, Vassos E, Bergh S, et al. Association between schizophrenia polygenic score and psychotic symptoms in Alzheimer disease: meta-analysis of 11 cohort studies. bioRxiv. 2019:528802.","DOI":"10.1101\/528802"},{"key":"1074_CR42","doi-asserted-by":"crossref","first-page":"761","DOI":"10.3233\/JAD-2010-1274","volume":"19","author":"MA DeMichele-Sweet","year":"2010","unstructured":"DeMichele-Sweet MA, Sweet RA. Genetics of psychosis in Alzheimer disease: a review. J Alzheimers Dis. 2010;19:761\u201380.","journal-title":"J Alzheimers Dis"},{"key":"1074_CR43","doi-asserted-by":"crossref","first-page":"e574","DOI":"10.1038\/tp.2015.64","volume":"5","author":"X Zheng","year":"2015","unstructured":"Zheng X, Demirci FY, Barmada MM, Richardson GA, Lopez OL, Sweet RA, et al. Genome-wide copy-number variation study of psychosis in Alzheimer\u2019s disease. Transl Psychiatry. 2015;5:e574.","journal-title":"Transl Psychiatry"},{"key":"1074_CR44","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1001\/archneur.58.3.466","volume":"58","author":"RA Sweet","year":"2001","unstructured":"Sweet RA, Hamilton RL, Healy MT, Wisniewski SR, Henteleff R, Pollock BG, et al. Alterations of striatal dopamine receptor binding in Alzheimer disease are associated with Lewy body pathology and antemortem psychosis. Arch Neurol. 2001;58:466\u201372.","journal-title":"Arch Neurol"},{"key":"1074_CR45","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1093\/brain\/aww359","volume":"140","author":"S Reeves","year":"2017","unstructured":"Reeves S, McLachlan E, Bertrand J, D\u2019Antonio F, Brownings S, Nair A, et al. Therapeutic window of dopamine D2\/3 receptor occupancy to treat psychosis in Alzheimer's disease. Brain. 2017;140:1117\u201327.","journal-title":"Brain"},{"key":"1074_CR46","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1038\/nature13595","volume":"511","author":"Schizophrenia Working Group of the Psychiatric Genomics C","year":"2014","unstructured":"Schizophrenia Working Group of the Psychiatric Genomics C. Biological insights from 108 schizophrenia-associated genetic loci. Nature. 2014;511:421\u20137.","journal-title":"Nature"},{"key":"1074_CR47","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1097\/JGP.0b013e3181557b47","volume":"15","author":"JE Mintzer","year":"2007","unstructured":"Mintzer JE, Tune LE, Breder CD, Swanink R, Marcus RN, McQuade RD, et al. Aripiprazole for the treatment of psychoses in institutionalized patients with Alzheimer dementia: a multicenter, randomized, double-blind, placebo-controlled assessment of three fixed doses. Am J Geriatr Psychiatry. 2007;15:918\u201331.","journal-title":"Am J Geriatr Psychiatry"},{"key":"1074_CR48","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1001\/archneur.1991.00530180075020","volume":"48","author":"GS Zubenko","year":"1991","unstructured":"Zubenko GS, Moossy J, Martinez AJ, Rao G, Claassen D, Rosen J, et al. Neuropathologic and neurochemical correlates of psychosis in primary dementia. Arch Neurol. 1991;48:619\u201324.","journal-title":"Arch Neurol"},{"key":"1074_CR49","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/j.neuropsychologia.2004.06.007","volume":"43","author":"M Garcia-Alloza","year":"2005","unstructured":"Garcia-Alloza M, Gil-Bea FJ, Diez-Ariza M, Chen CPLH, Francis PT, Lasheras B, et al. Cholinergic-serotonergic imbalance contributes to cognitive and behavioral symptoms in Alzheimer\u2019s disease. Neuropsychologia. 2005;43:442\u20139.","journal-title":"Neuropsychologia"},{"key":"1074_CR50","doi-asserted-by":"crossref","first-page":"43","DOI":"10.3233\/JAD-2008-14104","volume":"14","author":"B Marcos","year":"2008","unstructured":"Marcos B, Garc\u00eda-Alloza M, Gil-Bea FJ, Chuang TT, Francis PT, Chen CP, et al. Involvement of an altered 5-HT -{6} receptor function in behavioral symptoms of Alzheimer\u2019s disease. J Alzheimers Dis. 2008;14:43\u201350.","journal-title":"J Alzheimers Dis"},{"key":"1074_CR51","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1192\/bjp.165.1.53","volume":"165","author":"H Forstl","year":"1994","unstructured":"Forstl H, Burns A, Levy R, et al. Neuropathological correlates of psychotic phenomena in confirmed Alzheimer\u2019s disease. Br J Psychiatry. 1994;165:53\u20139.","journal-title":"Br J Psychiatry"},{"key":"1074_CR52","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1038\/nrneurol.2009.39","volume":"5","author":"CG Ballard","year":"2009","unstructured":"Ballard CG, Gauthier S, Cummings JL, Brodaty H, Grossberg GT, Robert P, et al. Management of agitation and aggression associated with Alzheimer disease. Nat Rev Neurol. 2009;5:245\u201355.","journal-title":"Nat Rev Neurol"},{"key":"1074_CR53","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1016\/j.jagp.2012.11.001","volume":"22","author":"B Creese","year":"2014","unstructured":"Creese B, Ballard C, Aarsland D, Londos E, Sharp S, Jones E. Determining the association of the5HTTLPR polymorphism with delusions and hallucinations in Lewy body dementias. Am J Geriatr Psychiatry. 2014;22:580\u20136.","journal-title":"Am J Geriatr Psychiatry"},{"key":"1074_CR54","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1212\/WNL.57.5.805","volume":"57","author":"PL MK","year":"2001","unstructured":"MK PL, Lai OF, Keene J, et al. Psychosis of Alzheimer\u2019s disease is associated with elevated muscarinic M2 binding in the cortex. Neurology. 2001;57:805.","journal-title":"Neurology"},{"key":"1074_CR55","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1007\/s00213-008-1124-9","volume":"198","author":"SW Tsang","year":"2008","unstructured":"Tsang SW, Francis PT, Esiri MM, et al. Loss of [3H]4-DAMP binding to muscarinic receptors in the orbitofrontal cortex of Alzheimer\u2019s disease patients with psychosis. Psychopharmacology. 2008;198:251\u20139.","journal-title":"Psychopharmacology"},{"key":"1074_CR56","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1002\/1531-8249(200012)48:6<868::AID-ANA7>3.0.CO;2-0","volume":"48","author":"C Ballard","year":"2000","unstructured":"Ballard C, Piggott M, Johnson M, Cairns N, Perry R, McKeith I, et al. Delusions associated with elevated muscarinic binding in dementia with Lewy bodies. Ann Neurol. 2000;48:868\u201376.","journal-title":"Ann Neurol"},{"key":"1074_CR57","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1111\/j.1471-4159.1990.tb03162.x","volume":"55","author":"EK Perry","year":"1990","unstructured":"Perry EK, Marshall E, Kerwin J, Smith CJ, Jabeen S, Cheng AV, et al. Evidence of a monoaminergic-cholinergic imbalance related to visual hallucinations in Lewy body dementia. J Neurochem. 1990;55:1454\u20136.","journal-title":"J Neurochem"},{"key":"1074_CR58","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1001\/archpsyc.57.12.1165","volume":"57","author":"NB Farber","year":"2000","unstructured":"Farber NB, Rubin EH, Newcomer JW, Kinscherf DA, Miller JP, Morris JC, et al. Increased neocortical neurofibrillary tangle density in subjects with Alzheimer disease and psychosis. Arch Gen Psychiatry. 2000;57:1165\u201373.","journal-title":"Arch Gen Psychiatry"},{"key":"1074_CR59","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1002\/ana.72","volume":"49","author":"S Tekin","year":"2001","unstructured":"Tekin S, Mega MS, Masterman DM, Chow T, Garakian J, Vinters HV, et al. Orbitofrontal and anterior cingulate cortex neurofibrillary tangle burden is associated with agitation in Alzheimer disease. Ann Neurol. 2001;49:355\u201361.","journal-title":"Ann Neurol"},{"key":"1074_CR60","doi-asserted-by":"crossref","first-page":"S80","DOI":"10.1016\/j.jagp.2012.12.105","volume":"21","author":"PS Murray","year":"2013","unstructured":"Murray PS, Kirkwood CM, Ikonomovic MD, Fish KN, Sweet RA. Tau phosphorylation is exaggerated in Alzheimer disease with psychosis. Am J Geriatr Psychiatry. 2013;21:S80\u2013S1.","journal-title":"Am J Geriatr Psychiatry"},{"key":"1074_CR61","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1176\/appi.ajp.2013.13040466","volume":"170","author":"J Koppel","year":"2013","unstructured":"Koppel J, Sunday S, Buthorn J, Goldberg T, Davies P, Greenwald B, et al. Elevated CSF tau is associated with psychosis in Alzheimer\u2019s disease. Am J Psychiatry. 2013;170:1212\u20133.","journal-title":"Am J Psychiatry"},{"key":"1074_CR62","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1016\/j.jamda.2014.08.011","volume":"15","author":"B Creese","year":"2014","unstructured":"Creese B, Corbett A, Jones E, Fox C, Ballard C. Role of the extended MAPT haplotype in the worsening of psychotic symptoms and treatment response in Alzheimer disease. J Am Med Dir Assoc. 2014;15:934\u20137.","journal-title":"J Am Med Dir Assoc"},{"key":"1074_CR63","doi-asserted-by":"crossref","first-page":"2807","DOI":"10.1016\/j.neurobiolaging.2012.02.015","volume":"33","author":"PS Murray","year":"2012","unstructured":"Murray PS, Kirkwood CM, Gray MC, Ikonomovic MD, Paljug WR, Abrahamson EE, et al. \u03b2-Amyloid 42\/40 ratio and kalirin expression in Alzheimer disease with psychosis. Neurobiol Aging. 2012;33:2807\u201316.","journal-title":"Neurobiol Aging"},{"key":"1074_CR64","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.neurobiolaging.2017.02.006","volume":"54","author":"JM Krivinko","year":"2017","unstructured":"\u2022 Krivinko JM, Erickson SL, Abrahamson EE, et al. Kalirin reduction rescues psychosis-associated behavioral deficits in APPswe\/PSEN1dE9 transgenic mice. Neurobiol Aging. 2017;54:59\u201370. Preclinical animal study providing further support for kalirin as a novel therapautic target for psychosis in AD.","journal-title":"Neurobiol Aging"},{"key":"1074_CR65","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1176\/appi.ajp.2018.17080858","volume":"175","author":"JM Krivinko","year":"2018","unstructured":"Krivinko JM, Erickson SL, Ding Y, Sun Z, Penzes P, MacDonald ML, et al. Synaptic proteome compensation and resilience to psychosis in Alzheimer\u2019s disease. Am J Psychiatr. 2018;175:999\u20131009.","journal-title":"Am J Psychiatr"},{"key":"1074_CR66","doi-asserted-by":"crossref","unstructured":"Kales HC, Gitlin LN, Lyketsos CG. Assessment and management of behavioral and psychological symptoms of dementia. BMJ (Clinical research ed). 2015;350 h369-h.","DOI":"10.1136\/bmj.h369"},{"key":"1074_CR67","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.cnur.2005.09.006","volume":"41","author":"M Smith","year":"2006","unstructured":"Smith M, Hall GR, Gerdner L, Buckwalter KC. Application of the progressively lowered stress threshold model across the continuum of care. Nurs Clin North Am. 2006;41:57\u201381 vi.","journal-title":"Nurs Clin North Am"},{"key":"1074_CR68","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1017\/S1041610218000534","volume":"31","author":"HC Kales","year":"2019","unstructured":"\u2022\u2022 Kales HC, Lyketsos CG, Miller EM, et al. Management of behavioral and psychological symptoms in people with Alzheimer\u2019s disease: an international Delphi consensus. Int Psychogeriatr. 2019;31:83\u201390. New consensus guidelines for the management of neuropsychiatric symptoms in AD.","journal-title":"Int Psychogeriatr"},{"key":"1074_CR69","doi-asserted-by":"crossref","unstructured":"Kales HC, Gitlin LN, Lyketsos CG. State of the art review: assessment and management of behavioral and psychological symptoms of dementia. BMJ. 2015;350.","DOI":"10.1136\/bmj.h369"},{"key":"1074_CR70","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1192\/bjp.bp.115.176438","volume":"209","author":"D Freeman","year":"2016","unstructured":"Freeman D, Bradley J, Antley A, Bourke E, DeWeever N, Evans N, et al. Virtual reality in the treatment of persecutory delusions: randomised controlled experimental study testing how to reduce delusional conviction. Br J Psychiatry. 2016;209:62\u20137.","journal-title":"Br J Psychiatry"},{"key":"1074_CR71","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1002\/cpp.1962","volume":"23","author":"R Wilson","year":"2016","unstructured":"Wilson R, Collerton D, Freeston M, Christodoulides T, Dudley R. Is seeing believing? The process of change during cognitive-behavioural therapy for distressing visual hallucinations. Clin Psychol Psychother. 2016;23:285\u201397.","journal-title":"Clin Psychol Psychother"},{"key":"1074_CR72","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1097\/00019442-199522330-00003","volume":"3","author":"S Holroyd","year":"1995","unstructured":"Holroyd S, Sheldon-Keller A. A study of visual hallucinations in Alzheimer\u2019s disease. Am J Geriatr Psychiatry. 1995;3:198\u2013205.","journal-title":"Am J Geriatr Psychiatry"},{"key":"1074_CR73","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.1176\/ajp.156.12.1983","volume":"156","author":"FM Chapman","year":"1999","unstructured":"Chapman FM, Dickinson J, McKeith I, et al. Association among visual hallucinations, visual acuity, and specific eye pathologies in Alzheimer\u2019s disease: treatment implications. Am J Psychiatr. 1999;156:1983\u20135.","journal-title":"Am J Psychiatr"},{"key":"1074_CR74","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1007\/s11940-012-0166-9","volume":"14","author":"A Corbett","year":"2012","unstructured":"Corbett A, Smith J, Creese B, Ballard C. Treatment of behavioral and psychological symptoms of Alzheimer\u2019s disease. Curr Treat Options Neurol. 2012;14:113\u201325.","journal-title":"Curr Treat Options Neurol"},{"key":"1074_CR75","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1097\/01.JGP.0000200589.01396.6d","volume":"14","author":"LS Schneider","year":"2006","unstructured":"Schneider LS, Dagerman K, Insel PS. Efficacy and adverse effects of atypical antipsychotics for dementia: meta-analysis of randomized, placebo-controlled trials. Am J Geriatr Psychiatry. 2006;14:191\u2013210.","journal-title":"Am J Geriatr Psychiatry"},{"key":"1074_CR76","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1038\/nrn1926","volume":"7","author":"C Ballard","year":"2006","unstructured":"Ballard C, Howard R. Neuroleptic drugs in dementia: benefits and harm. Nat Rev Neurosci. 2006;7:492\u2013500.","journal-title":"Nat Rev Neurosci"},{"key":"1074_CR77","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1176\/appi.ajp.2007.06101710","volume":"164","author":"HC Kales","year":"2007","unstructured":"Kales HC, Valenstein M, Kim HM, et al. Mortality risk in patients with dementia treated with antipsychotics versus other psychiatric medications. Am J Psychiatr. 2007;164:1568\u201376.","journal-title":"Am J Psychiatr"},{"key":"1074_CR78","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1176\/appi.ajp.2011.11030347","volume":"169","author":"HC Kales","year":"2012","unstructured":"Kales HC, Kim HM, Zivin K, Valenstein M, Seyfried LS, Chiang C, et al. Risk of mortality among individual antipsychotics in patients with dementia. Am J Psychiatry. 2012;169:71\u20139.","journal-title":"Am J Psychiatry"},{"key":"1074_CR79","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1001\/jamapsychiatry.2014.3018","volume":"72","author":"DT Maust","year":"2015","unstructured":"Maust DT, Kim HM, Seyfried LS, Chiang C, Kavanagh J, Schneider LS, et al. Antipsychotics, other psychotropics, and the risk of death in patients with dementia: number needed to harm. JAMA Psychiatry. 2015;72:438\u201345.","journal-title":"JAMA Psychiatry"},{"key":"1074_CR80","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/S0140-6736(13)62106-6","volume":"383","author":"J Cummings","year":"2014","unstructured":"Cummings J, Isaacson S, Mills R, Williams H, Chi-Burris K, Corbett A, et al. Pimavanserin for patients with Parkinson\u2019s disease psychosis: a randomised, placebo-controlled phase 3 trial. Lancet. 2014;383:533\u201340.","journal-title":"Lancet"},{"key":"1074_CR81","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/S1474-4422(18)30039-5","volume":"17","author":"C Ballard","year":"2018","unstructured":"\u2022\u2022 Ballard C, Banister C, Khan Z, et al. Evaluation of the safety, tolerability, and efficacy of pimavanserin versus placebo in patients with Alzheimer's disease psychosis: a phase 2, randomised, placebo-controlled, double-blind study. Lancet Neurol. 2018;17:213\u201322. Randomized control trial showiong efficacy of pimavanserin for psychosis in AD.","journal-title":"Lancet Neurol"},{"key":"1074_CR82","doi-asserted-by":"crossref","unstructured":"Ballard C, Isaacson S, Mills R, et al. Impact of current antipsychotic medications on comparative mortality and adverse events in people with Parkinson disease psychosis. Journal of the American Medical Directors Association. 2015;16:898.e1\u20137.","DOI":"10.1016\/j.jamda.2015.06.021"},{"key":"1074_CR83","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1177\/0891988715601735","volume":"29","author":"ME Peters","year":"2016","unstructured":"Peters ME, Vaidya V, Drye LT, Devanand DP, Mintzer JE, Pollock BG, et al. Citalopram for the treatment of agitation in Alzheimer dementia:genetic influences. J Geriatr Psychiatry Neurol. 2016;29:59\u201364.","journal-title":"J Geriatr Psychiatry Neurol"},{"key":"1074_CR84","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1176\/appi.ajp.2016.15020248","volume":"173","author":"AK Leonpacher","year":"2016","unstructured":"Leonpacher AK, Peters ME, Drye LT, et al. Effects of citalopram on neuropsychiatric symptoms in Alzheimer\u2019s dementia: evidence from the CitAD study. Am J Psychiatr. 2016;173:473\u201380.","journal-title":"Am J Psychiatr"},{"key":"1074_CR85","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1136\/jnnp.2003.029868","volume":"75","author":"P Pollak","year":"2004","unstructured":"Pollak P, Tison F, Rascol O, et al. Clozapine in drug induced psychosis in Parkinson\u2019s disease: a randomised, placebo controlled study with open follow up. J Neurol Neurosurg Psychiatry. 2004;75:689.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"1074_CR86","doi-asserted-by":"crossref","unstructured":"Low-dose clozapine for the treatment of drug-induced psychosis in Parkinson\u2019s disease. N Engl J Med. 1999;340:757\u201363.","DOI":"10.1056\/NEJM199903113401003"},{"key":"1074_CR87","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1097\/01.JGP.0000221293.91312.d3","volume":"14","author":"JL Cummings","year":"2006","unstructured":"Cummings JL, McRae T, Zhang R. Effects of donepezil on neuropsychiatric symptoms in patients with dementia and severe behavioral disorders. Am J Geriatr Psychiatry. 2006;14:605\u201312.","journal-title":"Am J Geriatr Psychiatry"},{"key":"1074_CR88","doi-asserted-by":"crossref","first-page":"341","DOI":"10.4088\/JCP.v69n0302","volume":"69","author":"GK Wilcock","year":"2008","unstructured":"Wilcock GK, Ballard CG, Cooper JA, Loft H. Memantine for agitation\/aggression and psychosis in moderately severe to severe Alzheimer\u2019s disease: a pooled analysis of 3 studies. J Clin Psychiatry. 2008;69:341\u20138.","journal-title":"J Clin Psychiatry"},{"key":"1074_CR89","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1002\/ana.23557","volume":"72","author":"E Mori","year":"2012","unstructured":"Mori E, Ikeda M, Kosaka K, on behalf of the Donepezil-DLB Study Investigators. Donepezil for dementia with Lewy bodies: a randomized, placebo-controlled trial. Ann Neurol. 2012;72:41\u201352.","journal-title":"Ann Neurol"},{"key":"1074_CR90","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1097\/WAD.0000000000000161","volume":"31","author":"DP Devanand","year":"2017","unstructured":"Devanand DP, Pelton GH, D'Antonio K, et al. Low-dose lithium treatment for agitation and psychosis in Alzheimer disease and frontotemporal dementia: a case series. Alzheimer Dis Assoc Disord. 2017;31:73\u20135.","journal-title":"Alzheimer Dis Assoc Disord"},{"key":"1074_CR91","doi-asserted-by":"crossref","first-page":"S16","DOI":"10.1097\/00002093-199703000-00004","volume":"11","author":"NC Bodick","year":"1997","unstructured":"Bodick NC, Offen WW, Shannon HE, et al. The selective muscarinic agonist xanomeline improves both the cognitive deficits and behavioral symptoms of Alzheimer disease. Alzheimer Dis Assoc Disord. 1997;11:S16\u201322.","journal-title":"Alzheimer Dis Assoc Disord"}],"container-title":["Current Neurology and Neuroscience Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11910-020-01074-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11910-020-01074-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11910-020-01074-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,23]],"date-time":"2022-11-23T02:57:29Z","timestamp":1669172249000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11910-020-01074-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,13]]},"references-count":91,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["1074"],"URL":"https:\/\/doi.org\/10.1007\/s11910-020-01074-y","relation":{},"ISSN":["1528-4042","1534-6293"],"issn-type":[{"value":"1528-4042","type":"print"},{"value":"1534-6293","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,13]]},"assertion":[{"value":"7 September 2020","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 October 2020","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"Prof Ballard reports grants from Biomedical Research Unit for Dementia (BRU-D) and the Maudsley Biomedical Research Centre (BRC)-dementia theme at the King\u2019s College London, London, UK, during the conduct of the study; grants and personal fees from Acadia pharmaceutical company, grants and personal fees from Lundbeck, personal fees from Roche, personal fees from Otsuka, personal fees from Novartis, personal fees from Eli Lilly and personal fees from Pfizer, outside the submitted work. Prof Kales has royalties from the proceeds of the DICE Approach book. Prof Lyketsos wishes to acknowledge Johns Hopkins ADRC for supporting his time: P50AG005146. Prof Aarsland has received research support and\/or honoraria from Astra-Zeneca, H. Lundbeck, Novartis Pharmaceuticals and GE Health and served as paid consultant for H. Lundbeck, Eisai, Heptares and Mentis Cura. Dag Aarsland is a Royal Society Wolfson Research Merit Award Holder and would like to thank the Wolfson Foundation and the Royal Society for their support. This paper represents independent research [part] funded by the National Institute for Health Research (NIHR) Biomedical Research Centre at South London and Maudsley NHS Foundation Trust and King\u2019s College London. The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health and Social Care. Dr Creese has no conflicts to disclose. Dr Mills reports other from Acadia Pharmaceuticals and personal fees from Addex Therapeutics, outside the submitted work. In addition, Dr Mills has a patent Mills R and Williams H., Patent PCT\/US2013\/071792: Methods for the treatment of Parkinson\u2019s disease psychosis using pimavanserin; published 5 Jun 2014; pending. Dr Williams reports other from Acadia Pharmaceuticals and personal fees from Addex Pharmaceuticals, outside the submitted work; in addition, Dr Williams has a patent Mills R. and Williams H., Patent PCT\/US2013\/071792: Methods for the treatment of Parkinson\u2019s disease psychosis using pimavanserin; published 5 Jun 2014, pending. Dr Sweet has nothing to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}],"article-number":"57"}}